In focus
Latest feed
iPAX‑2 Trial of TLX101 TX in First‑Line Glioblastoma Finishes Enrollment and Locks In Dosing Schedule
iPAX‑2 Trial of TLX101 in First‑Line Glioblastoma Hits Full Enrollment and Dosing Confirmation
A Glimmer of Hope: UNC Researchers Uncover Potent Combination Therapy for Aggressive Brain Cancer
A New Chapter in Cancer Diagnostics: Humana Covers CNSide Assay
